Biotech ETF Overview

With 16 ETFs traded in the U.S. markets, Biotech ETFs gather total assets under management of $16.06B. The average expense ratio is 0.76%. Biotech ETFs can be found in the following asset classes:

  • Equity

The largest Biotech ETF is the iShares NASDAQ Biotechnology ETF IBB with $7.41B in assets. In the last trailing year, the best performing Biotech ETF was the BBH at 3.47%. The most-recent ETF launched in the Biotech space was the Global X Genomics & Biotechnology ETF GNOM in 04/05/19.

TOP ETF PERFORMERS

CNCR Loncar Cancer Immunotherapy ETF 4.20%
LABD Direxion Daily S&P Biotech Bear 3X Shares 2.26%
BBH VanEck Vectors Biotech ETF 0.99%
BBC Virtus LifeSci Biotech Clinical Trials ETF 0.73%
IBB iShares NASDAQ Biotechnology ETF 0.09%

BOTTOM ETF PERFORMERS

CHNA Loncar China BioPharma ETF -9.40%
LABU Direxion Daily S&P Biotech Bull 3X Shares -9.39%
BBP Virtus LifeSci Biotech Products ETF -3.40%
PBE Invesco Dynamic Biotechnology & Genome ETF -2.85%
GNOM Global X Genomics & Biotechnology ETF -2.68%

TOP CREATIONS

LABU Direxion Daily S&P Biotech Bull 3X Shares 108.69
FBT First Trust NYSE Arca Biotechnology Index Fund 101.18
XBI SPDR S&P Biotech ETF 84.46
BIB ProShares Ultra NASDAQ Biotechnology 35.15
IBB iShares NASDAQ Biotechnology ETF 22.34

TOP REDEMPTIONS

PBE Invesco Dynamic Biotechnology & Genome ETF -18.23
LABD Direxion Daily S&P Biotech Bear 3X Shares -17.69
BBH VanEck Vectors Biotech ETF -6.54
BIS ProShares UltraShort Nasdaq Biotechnology -1.83
ZBIO ProShares UltraPro Short Nasdaq Biotechnology -0.80

AUM WINNERS

GNOM Global X Genomics & Biotechnology ETF 94.19%
UBIO ProShares UltraPro Nasdaq Biotechnology 6.77%
CNCR Loncar Cancer Immunotherapy ETF 1.34%
BBC Virtus LifeSci Biotech Clinical Trials ETF 0.66%
XBI SPDR S&P Biotech ETF -0.46%

AUM LOSERS

ZBIO ProShares UltraPro Short Nasdaq Biotechnology -18.71%
LABD Direxion Daily S&P Biotech Bear 3X Shares -17.61%
BIS ProShares UltraShort Nasdaq Biotechnology -11.40%
CHNA Loncar China BioPharma ETF -10.00%
PBE Invesco Dynamic Biotechnology & Genome ETF -8.79%

ETF Report

Smart Beta: Beyond The Hype

Despite all the buzz, advisors have reasons to be wary of such strategies.

Features and News

Politics Weigh On Health Care ETFs

Fears of Medicare-for-all are weighing on health care ETFs. Is this an opportunity?

Daily ETF Watch

ETF Week: Zero-Fee Funds Debut

Plus, the first space ETF rolls out.

Features and News

Worst Performing ETFs Of The Year

These ETFs stand out for their poor performance in a strong year for financial markets.

ETF Report

Sectors In Review: April 2019

Sector ETFs had a mostly positive February.

ETF Report

2018 ETF.com Annual Awards

From the ETF of the Year to the People’s Choice ETF, we review the winners of each award, what drove their success and the finalists they competed against.

Features and News

CNBC ETF Edge: Biotech Getting Sick?

How you should trade biotech ETFs.

ETF Report

 Sectors In Review: January 2019

November was mostly positive for sector ETFs.

ETF Report

 Sectors In Review: December 2018

Sector ETFs got clobbered in October.